Pulmonary Surfactant

Why pulmonary surfactant matters

• It makes breathing cheap. Without surfactant, the surface tension of the alveolar water lining would dominate lung mechanics, and inflating the lungs would require several times the muscular effort. Surfactant lowers the work of breathing by roughly an order of magnitude — the difference between quiet, effortless respiration and the exhausting, grunting struggle of a surfactant-deficient newborn.
• It stabilizes 300 million alveoli of different sizes. The adult lung holds on the order of 300–500 million alveoli, each roughly 200–300 µm across, sharing walls and connected by pores. Constant surface tension would let every small alveolus dump its air into a larger neighbor. Surfactant's area-dependent tension keeps sacs of unequal size mechanically stable side by side.
• It keeps the alveoli dry. High surface tension in the air sac lowers interstitial pressure and sucks fluid out of the pulmonary capillaries into the airspace (a Starling-force effect). By reducing tension, surfactant reduces this transudation, which is one reason surfactant dysfunction contributes to the pulmonary edema of acute respiratory distress syndrome (ARDS) in adults.
• Its absence is a leading killer of premature infants. Neonatal respiratory distress syndrome (NRDS) was, for decades, the single most common cause of death in preterm babies. The combination of antenatal corticosteroids and exogenous surfactant replacement has cut its mortality dramatically since the 1990s.
• It is part of innate immunity. The hydrophilic surfactant proteins SP-A and SP-D are collectins — they bind sugars on the surface of inhaled bacteria, viruses, and fungi and hand them to alveolar macrophages. The lung's first defensive layer is, quite literally, the same film that keeps it open.
• It is a drug delivered by the vial. Modern surfactant preparations — poractant alfa (Curosurf, from pig lung), beractant (Survanta, from cow lung), calfactant (Infasurf) — are among the clearest examples of a native biological material purified and instilled directly into the organ that lacks it, with an immediate, visible improvement in oxygenation.

Common misconceptions

• "Surfactant is a detergent that dissolves mucus." It is a surface-active agent, but its job is to lower the surface tension of the alveolar water lining, not to break down secretions. The word "surfactant" simply means surface-active agent; the biological molecule is a specific lipid-protein complex, not a soap.
• "It's mostly protein because proteins do the work." Surfactant is about 90% lipid by mass. The single molecule that does the mechanical heavy lifting is a lipid — DPPC — because its two fully saturated palmitic-acid tails let it pack into a rigid film that survives compression to near-zero tension. The proteins are essential helpers, not the main active ingredient.
• "Type I cells make surfactant." No — the thin, flat type I pneumocytes cover ~95% of the alveolar surface and are built for gas diffusion; they make no surfactant. The cuboidal type II pneumocytes, far fewer in surface area, are the secretory and stem cells that synthesize, store, secrete, and recycle surfactant.
• "Laplace's law says small alveoli always collapse." That is only true if surface tension is constant. The whole point of surfactant is that tension is dynamic: it falls as the film is compressed in a shrinking alveolus, so 2T/r does not blow up as r falls. The law is not violated — surfactant changes the T term breath by breath.
• "Once made, surfactant just sits there." Surfactant is continuously turned over. The used film is taken back up by type II cells and alveolar macrophages, and a large fraction is recycled rather than degraded. Defects in this clearance pathway (for example loss of GM-CSF signaling) cause pulmonary alveolar proteinosis, where surfactant accumulates and floods the airspaces.
• "Giving oxygen fixes surfactant deficiency." Oxygen and pressure support the infant while the underlying problem — collapsing alveoli — persists. What actually reverses NRDS is replacing the surfactant itself (or, prophylactically, accelerating its production with antenatal steroids). High oxygen and barotrauma can even worsen the lung injury.

How pulmonary surfactant works

Start at the surface. Every alveolus is lined by a film of water only a fraction of a micron thick. At any air-water interface the water molecules cohere strongly, giving a surface tension near 70 mN/m — the same force that lets a water strider stand on a pond and that pulls a droplet into a sphere. In a curved alveolus that tension generates an inward, collapsing pressure described by the Law of Laplace: for a spherical surface with a single air-liquid interface, P = 2T/r, where T is surface tension and r is the radius. Smaller alveoli therefore feel a stronger collapsing pressure than large ones — a recipe for instability in which small sacs empty into big ones.

Type II alveolar cells solve this. In their endoplasmic reticulum and Golgi they synthesize phospholipids — above all dipalmitoylphosphatidylcholine (DPPC), a phosphatidylcholine bearing two saturated 16-carbon palmitic-acid tails — together with the four surfactant proteins. These are packed into lamellar bodies, organelles of concentric membrane whorls that look like an onion in the electron microscope. When the cell is stretched by a breath or stimulated by beta-agonists or ATP, lamellar bodies fuse with the apical membrane and dump their contents into the aqueous lining by exocytosis. There the material unfurls into a cross-hatched lattice called tubular myelin, a reservoir that feeds phospholipid to the interface.

At the interface, DPPC molecules orient with their two saturated tails sticking up into the air and their phosphate head groups anchored in the water. This monolayer disrupts the cohesive hydrogen-bond network of the water surface, lowering resting tension to about 25 mN/m. The magic is what happens on compression. As an alveolus shrinks during exhalation, the film is squeezed into a smaller area; the tightly packing, rigid DPPC molecules crowd together (helped by SP-B and SP-C, which squeeze fluid unsaturated lipids out of the film), and surface tension plummets toward < 5 mN/m — approaching zero. Because tension falls faster than radius, the collapsing pressure 2T/r actually decreases as the alveolus gets smaller, so small alveoli stop emptying. On the next inhalation the film re-spreads and tension climbs again, so large alveoli, with their surfactant thinned out, resist over-inflation. This area-dependent, hysteretic tension is what mechanically stabilizes a lung full of unequal sacs and slashes the work of breathing.

Finally, the whole system is recycled. Spent surfactant is re-internalized by type II cells and cleared by alveolar macrophages, then either broken down or reassembled into fresh lamellar bodies. Developmentally, type II cells begin making surfactant around 24–28 weeks of gestation, with a sharp rise near 34–35 weeks driven by cortisol and thyroid hormone — which is exactly why a baby born too early has too little.

Pulmonary surfactant vs. airway mucus

Both are secreted liquids lining the respiratory tract, and they are frequently confused. They are made by different cells, in different places, for opposite jobs.

Feature	Pulmonary surfactant	Airway mucus
Where	Alveoli (gas-exchange zone)	Conducting airways (trachea, bronchi)
Secreting cell	Type II pneumocytes	Goblet cells, submucosal glands
Main components	~90% lipid (DPPC) + SP-A/B/C/D	Mucin glycoproteins (MUC5AC/5B) + water
Primary job	Lower surface tension, prevent alveolar collapse	Trap particles, mucociliary clearance
Key physical property	Surface activity (low, variable tension)	Viscoelastic gel that cilia can propel
Failure disease	Neonatal RDS, ARDS, alveolar proteinosis	Cystic fibrosis, chronic bronchitis, COPD
Immune role	SP-A/SP-D opsonize pathogens	Traps and expels pathogens; IgA, defensins

What surfactant is made of, component by component

Component	Rough share	Role
DPPC (dipalmitoyl-PC)	~40% of lipid	The disaturated workhorse; packs on compression to drive tension toward zero
Other phospholipids (unsaturated PC, PG, PE, PI)	~40% of lipid	Fluidize the film so it spreads fast; PG is a marker of maturity
Cholesterol & neutral lipids	~10% of lipid	Modulate film fluidity and phase behavior
SP-B	~1–2% (hydrophobic)	Adsorption & spreading; refines film on compression — absence is lethal at term
SP-C	~1% (hydrophobic)	Stabilizes the film; mutations cause interstitial lung disease
SP-A	~50% of protein (hydrophilic)	Most abundant surfactant protein; collectin: opsonization, tubular myelin formation, turnover control
SP-D	hydrophilic	Collectin: pathogen binding, immune regulation, surfactant homeostasis

Famous experiments and history

• Pattle (1955) and Clements (1957). Richard Pattle in Britain noticed that the bubbles in lung edema foam were extraordinarily stable and inferred an "insoluble protein" lowering surface tension. John Clements in the United States built a modified surface-balance (a Wilhelmy-type trough) and measured directly that lung extracts lowered surface tension far below water's and, crucially, that the tension changed with surface area — the area-dependence that explains alveolar stability. Together they established that a real, measurable surface-active lining exists in the lung.
• Avery and Mead (1959). Mary Ellen Avery, working with Jere Mead at Harvard, compared lung extracts from infants who died of hyaline membrane disease with those who died of other causes. The affected lungs lacked the surface-tension-lowering activity. This single paper — "Surface properties in relation to atelectasis and hyaline membrane disease" — pinned neonatal RDS on surfactant deficiency and reframed a mysterious killer as a treatable biochemical shortage.
• Liggins and Howie (1972). While studying preterm labor in sheep, Graham Liggins found that glucocorticoids accelerated fetal lung maturation. The landmark Liggins and Howie randomized trial in humans showed that giving the mother betamethasone before preterm delivery cut RDS and neonatal death — the origin of antenatal corticosteroid therapy still used worldwide.
• Gluck's L/S ratio (1971). Louis Gluck showed that the ratio of lecithin to sphingomyelin in amniotic fluid rises as the fetal lung matures, giving obstetricians the first practical test of fetal lung maturity and a way to time risky deliveries.
• Fujiwara (1980). Tetsuro Fujiwara in Japan reported the first successful use of an exogenous surfactant — a modified extract of bovine lung — instilled into the tracheas of premature infants with RDS, with rapid improvement in oxygenation. This launched the era of surfactant replacement therapy; the U.S. FDA approved the first product in 1990.
• A famous patient. On August 7, 1963, Patrick Bouvier Kennedy, son of President John F. Kennedy, was born at about 34 weeks and died two days later of hyaline membrane disease. At the time no effective treatment existed. His death is often credited with spurring investment in neonatal respiratory research in the years that produced today's surfactant therapies.